BioReview Admin

A single glowing amber drop suspended over a smooth slate-blue clinical surface

Markets

A Decades-Old Thyroid Hormone Just Commanded a $560 Million Takeover

ANI Pharmaceuticals' $560 million offer for Egetis turns on Emcitate, the first approved drug for MCT8 deficiency, an ultra-rare thyroid disorder, built on a decades-old hormone analog.

3D illustration of a mantle cell lymphoma B cell with a targeted inhibitor molecule docking to its surface

Pharmaceuticals

FDA Grants Priority Review to Chemo-Free BRUKINSA Combo in Untreated MCL

The FDA has granted Priority Review to a chemotherapy-free BRUKINSA plus rituximab regimen for previously untreated mantle cell lymphoma, backed by a Phase 3 trial showing a 43% cut in the risk of progression or death.